Mumbai's Transasia acquires Drew Scientific, JAS Diagnostics Inc

In its fifth acquisition this year, Mumbai-based medical diagnostics products maker Transasia Bio-Medicals Ltd Transasia Bio-Medicals today said it had acquired two more US-based companies - Drew Scientific and JAS Diagnostics Inc. from Escalon Medical

It said the acquisitions are aimed at expanding its glibal markets.

The acquisition was made through Transasia's subsidiary, Erba Diagnostics USA. It has acquired the entire business assets including plant and intellectual assets, which will become a direct wholly-owned subsidiary of Erba Diagnostics.

Transasia's acquisition of Drew marks the entry in the fast growing segment of diabetes management worldwide. It would benefit with the capabilities to offer proprietary Liquid Chromatography based Glycated hemoglobin analyzers and reagents to the laboratories worldwide. Glycated haemoglobin analysis by Liquid Chromatography is the method of choice in monitoring long term glycemic control in diabetics.

JAS Diagnostics Inc. is a manufacturer of clinical chemistry reagents. It supplies chemistry reagents that it has developed through its own indigenous R&D. It offers solutions with excellent stability in different formats of systems packs, liquid reagents and powder reagents.

According to sources, diabetes affects an estimated 250 million people worldwide with nearly 60 per cent residing in India and China alone. An estimated 90 million people are affected in China followed by 60 million in India and 25 million people are affected in North America signalling a huge opportunity and the strategic nature of this acquisition.